Physician profile
James William Wallace
NPI 1336182930
$10,691.90
in general payments reported to CMS, 2019-2025
34 companies · $2,199 in 2025
The $2,199 reported for 2025 was more than what 90% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,200 · 2020: $323 · 2021: $1,190 · 2022: $1,241 · 2023: $1,771 · 2024: $1,768 · 2025: $2,199.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,738.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,737.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,744.87 | 2021-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $1,644.82 | 2019-2025 | Rexulti, Abilify Maintena, Nuedexta |
| Abbvie INC. | $1,026.85 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $877.24 | 2021-2025 | Qelbree, Qelbree |
| Neurocrine Biosciences, INC. | $626.19 | 2019-2025 | Ingrezza |
| Alkermes, INC. | $558.71 | 2021-2025 | Aristada, Lybalvi |
| Sunovion Pharmaceuticals INC. | $525.77 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $405.92 | 2019-2025 | Spravato, Invega Sustenna |
| Takeda Pharmaceuticals U.S.A., INC. | $330.76 | 2019-2025 | Trintellix |
| Corium, LLC | $302.73 | 2021-2025 | Azstarys |
| Tris Pharma INC | $291.85 | 2019-2025 | Dyanavel Xr |
| Bausch Health US, LLC | $287.85 | 2019-2025 | Wellbutrin, Aplenzin |
| Axsome Therapeutics, INC. | $244.35 | 2022-2025 | Auvelity |
| Vanda Pharmaceuticals INC. | $241.34 | 2025 | Fanapt |
| Neos Therapeutics, LP | $220.66 | 2019-2024 | Adzenys Xr-Odt |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $195.88 | 2019-2020 | |
| Lundbeck LLC | $189.61 | 2019-2025 | Rexulti |
| Avanir Pharmaceuticals, INC. | $125.63 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $96.78 | 2025 | Cobenfy |
| Ironshore Pharmaceuticals INC. | $95.26 | 2019-2024 | Jornay Pm |
| Idorsia Pharmaceuticals US INC | $79.89 | 2022-2024 | Quviviq |
| Noven Therapeutics, LLC | $75.91 | 2021-2024 | Xelstrym |
| Adlon Therapeutics L.P. | $65.83 | 2019-2020 | |
| Collegium Pharmaceutical, INC. | $63.34 | 2025 | Jornay Pm |
| Almatica Pharma LLC | $60.80 | 2021-2025 | Loreev Xr |
| Jazz Pharmaceuticals INC. | $57.42 | 2019-2020 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $50.23 | 2025 | Rejoyn |
| Vertical Pharmaceuticals, LLC | $46.83 | 2019-2024 | Relexxii |
| Kowa Pharmaceuticals America, INC. | $37.56 | 2022 | |
| Merck Sharp & Dohme LLC | $36.60 | 2023 | Belsomra |
| Shire North American Group INC | $28.03 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $20.01 | 2023 | Austedo Xr |
| Neuronetics, INC. | $18.64 | 2019 | |
| Pfizer INC. | $17.74 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Wallace listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.